Published in Cancer Weekly, January 18th, 2005
In preclinical testing TPI 287 demonstrated the ability to inhibit tumor cell growth in a number of in vitro cell lines and has shown superior inhibition of tumor burden in certain animal xenograft models when tested against standard comparative agents.
The in vitro activity was seen across multiple cell lines including those cell lines known to be sensitive to taxanes as well as cell lines known to be resistant to currently available taxanes. Taxane resistant cell lines in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.